Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40ZST | ISIN: US59267L1070 | Ticker-Symbol:
NASDAQ
06.06.25 | 17:01
27,505 US-Dollar
-3,91 % -1,120
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
METSERA INC Chart 1 Jahr
5-Tage-Chart
METSERA INC 5-Tage-Chart

Aktuelle News zur METSERA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoMetsera, Inc.: Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association2
27.05.Cantor Fitzgerald maintains overweight on Metsera shares2
13.05.Metsera GAAP EPS of -$1.03 misses by $0.282
12.05.Metsera Posts Wider Loss In Q11
12.05.Metsera, Inc. - 10-Q, Quarterly Report1
12.05.Metsera, Inc. - 8-K, Current Report4
METSERA Aktie jetzt für 0€ handeln
12.05.Metsera, Inc.: Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress315MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is in three ongoing VESPER Phase 2b trials, with data from VESPER-1 expected in mid-2025 MET-233i, a monthly, ultra-long...
► Artikel lesen
28.04.Metsera, Inc. - 8-K, Current Report2
17.04.Why did Lilly data for oral GLP-1 boost Structure and Metsera?10
14.04.Viking, Structure, Metsera on a tear as Pfizer drops obesity pill5
27.03.Metsera reports Q4 results6
26.03.Metsera, Inc. - 10-K, Annual Report2
26.03.Metsera, Inc. Q4 Loss Rises1
26.03.Metsera, Inc. - 8-K, Current Report-
26.03.Metsera, Inc.: Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress872MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025 Multiple data readouts in mid and...
► Artikel lesen
15.03.Metsera, Inc. (MTSR): Among Top Insider Purchases Last Month4
10.03.Metsera, Inc. - 8-K, Current Report2
04.03.Why Did MTSR Stock Surge 15% On The Worst Trading Day Of 2025? Here's What Has Happened Since Its Listing1
27.02.CenExel Research: CenExel Supports Metsera, Inc. in Successful Phase II Trial of MET-097 for Obesity and Metabolic Diseases463SALT LAKE CITY, UTAH / ACCESS Newswire / February 27, 2025 / CenExel is pleased to announce its partnership with Metsera, Inc., a clinical-stage biopharmaceutical company dedicated to advancing treatments...
► Artikel lesen
25.02.Metsera started by Guggenheim at buy on obesity drug opportunity3
Weiter >>
57 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1